The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDCX | -40.14% | N/A | N/A | -58% |
| S&P | +13.22% | +85.17% | +13.11% | +40% |
Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company, which engages in investing in novel life sciences and bio-technology companies. It focuses on identifying, acquiring, and advancing relatively de-risked clinical stage assets through clinical development and commercialization. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.
No news articles found for Medicus Pharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $27.36M | -27.5% |
| Market Cap / Employee | $2.28M | 0.0% |
| Employees | 12 | 0.0% |
| Net Income | -$15.98M | -440.1% |
| EBITDA | -$6.71M | -125.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.66M | 63.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.12M | -47.3% |
| Short Term Debt | $6.93M | 6063.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -376.27% | -165.3% |
| Return On Invested Capital | -406.06% | 176.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.83M | -122.0% |
| Operating Free Cash Flow | -$6.83M | -122.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.55 | 14.02 | 18.68 | 11.36 | 5.06% |
| Price to Tangible Book Value | 7.55 | 14.02 | 18.68 | 11.36 | -2.96% |
| Enterprise Value to EBITDA | -8.35 | -8.16 | -6.32 | -6.20 | -11.50% |
| Return on Equity | -525.4% | -1882.0% | -340.5% | -2287.7% | 600.86% |
| Total Debt | $0.32M | $0.29M | $4.97M | $7.05M | 1920.66% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
